Without the right support to supplement GLP-1 medication benefit offerings like Ozempic and Wegovy, organizations are missing out on the potential of any weight loss solution they offer now or in the future.
Over 50% of employees want weight loss drugs covered through their benefits, according to data from medical billing company Tebra. However, fewer than 1 in 5 companies cover such drugs, according to a recent peer-reviewed journal in Health Affairs, with only 3% saying they are likely to do so in the next year. Much of that apprehension has to do with how expensive and unreliable the medication can be — both of which digital healthcare platform FlyteHealth aims to address with their obesity care program.
